Andrx Picks Up Lovenox Generic Marketing Rights From Amphastar
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the $10 mil. deal, Andrx obtains rights to market two strengths of the injectable antithrombotic in the U.S. retail pharmacy market. Amphastar will be responsible for ongoing enoxaparin patent litigation with Sanofi-Aventis. The 30-month stay on Amphastar’s ANDA runs through February 2006.
You may also be interested in...
Lovenox Patent Invalidity Ruling Could Open Door To Near-Term Generics
California court invalidates Sanofi-Aventis’ patent due to inequitable conduct. The court’s ruling will lead to lifting of 30-month stay on ANDA approvals. Amphastar and Teva said they would await FDA approval of their enoxaparin generics before deciding whether to launch prior to an appellate court ruling.
Lovenox Patent Invalidity Ruling Could Open Door To Near-Term Generics
California court invalidates Sanofi-Aventis’ patent due to inequitable conduct. The court’s ruling will lead to lifting of 30-month stay on ANDA approvals. Amphastar and Teva said they would await FDA approval of their enoxaparin generics before deciding whether to launch prior to an appellate court ruling.
Lovenox Patent Could Be Reissued In Mid-2005, Sanofi-Aventis Says
Patent & Trademark Office allows Sanofi-Aventis’ reissuance application after twice rejecting the request. The company says reissuance of the ’618 patent, which expires in 2012, will bolster its position in litigation against enoxaparin ANDA filers.